Gapping down
In reaction to disappointing earnings/guidance: SCL -10%, ANGI -9.6%, ANGI -9.6%, ILMN -9.1%, LLTC -7.5%, EXPO -7.1%, AAPL -6.8%, TUP -6%, ARMH -4.8%, BEAV -4.1%, MSFT -3.6%, YHOO -2.3%, STJ -2.3%, PII -1.9%, EMC -1.5%, ABT -1%
M&A news: T -0.5%
Select metals/mining stocks trading lower: HL -3.6%, MT -3.1%, RIO -2.5%, GOLD -1.8%
Select oil/gas related names showing early weakness: SDRL -2.2%, RDS.A -1.8%, STO -1.5%, CHK -1.5%, TOT -1.4%
Other news: XOMA -68.2% (announces Phase 3 EYEGUARD-B Study did not meet the primary endpoint of time to first acute ocular exacerbation), IDI -18.8% (40%+ decline yesterday on cautious blog comments), ARRY -15.2% (AstraZeneca provides update on Selumetinib in uveal melanoma; did not meet its primary endpoint of progression free survival), VDSI -9.3% ( discloses it recently become aware that certain of its products which were sold by a VASCO European subsidiary to a third-party distributor may have been resold by the distributor to parties in Iran; sales may be in violation of U.S. economic sanctions), NVGN -8.7% (announces the resignation of CEO Dr Graham Kelly), RDUS -8.5% ( discloses that the FDA denied its re-request for breakthrough therapy designation for abaloparatide-SC, including the 18-month top-line results of its ACTIVE trial; announces a registered public offering of up to $250 million of its common stock), SWKS -5.9% (following AAPL results), EXEL -5.8% ( to offer 20 mln shares of its common stock ), CRUS -5.7% (in symp with AAPL), FXCM -5.4% (Board approved a 1-for-10 reverse split), FCSC -2.1% (commenced a public offering of common stock; size and price not disclosed), RGLS -4.9% (still checking), NXPI -4.8% (following AAPL results), BIIB -4.4% (disappointing Phase 1b data for 6 mg dose of aducanumab), AVGO -4.1% (following AAPL results), BHP -3.7% (reports FY15 gold production), STM -3.1% (in symp with AAPL), INVN -2.9% (following AAPL results), FIT -2.7% (cont vol post IPO), TSLA -1.8% (trading lower with the mkt), LLY -1.8% (announces results regarding solanezumab, that indicated the preservation of treatment effect in patients with mild Alzheimer's disease who received the drug early), FCSC -1.7% (commences a public offering of common stock), FB -1.6% (trading lower with the mkt),TWTR -1.2% (trading lower with the mkt), MU -1.1% (in symp with AAPL), DVAX -1% ( announces a public offering of common stock)
Analyst comments: BTU -5.8% (downgraded to Neutral from Overweight at JP Morgan), SD -3.8% (assumed with an Underperform at Credit Suisse), STM -3.1% (downgraded to Neutral at Citigroup), ALV -1.9% (downgraded to Neutral from Buy at BofA/Merrill ), AINV -1.7% (downgraded to Equal Weight from Overweight at Barclays ), CHK -1.5% (downgraded to Neutral from Outperform at Credit Suisse), EBAY -1% (downgraded to Mkt Perform from Outperform at Raymond James)
In reaction to disappointing earnings/guidance: SCL -10%, ANGI -9.6%, ANGI -9.6%, ILMN -9.1%, LLTC -7.5%, EXPO -7.1%, AAPL -6.8%, TUP -6%, ARMH -4.8%, BEAV -4.1%, MSFT -3.6%, YHOO -2.3%, STJ -2.3%, PII -1.9%, EMC -1.5%, ABT -1%
M&A news: T -0.5%
Select metals/mining stocks trading lower: HL -3.6%, MT -3.1%, RIO -2.5%, GOLD -1.8%
Select oil/gas related names showing early weakness: SDRL -2.2%, RDS.A -1.8%, STO -1.5%, CHK -1.5%, TOT -1.4%
Other news: XOMA -68.2% (announces Phase 3 EYEGUARD-B Study did not meet the primary endpoint of time to first acute ocular exacerbation), IDI -18.8% (40%+ decline yesterday on cautious blog comments), ARRY -15.2% (AstraZeneca provides update on Selumetinib in uveal melanoma; did not meet its primary endpoint of progression free survival), VDSI -9.3% ( discloses it recently become aware that certain of its products which were sold by a VASCO European subsidiary to a third-party distributor may have been resold by the distributor to parties in Iran; sales may be in violation of U.S. economic sanctions), NVGN -8.7% (announces the resignation of CEO Dr Graham Kelly), RDUS -8.5% ( discloses that the FDA denied its re-request for breakthrough therapy designation for abaloparatide-SC, including the 18-month top-line results of its ACTIVE trial; announces a registered public offering of up to $250 million of its common stock), SWKS -5.9% (following AAPL results), EXEL -5.8% ( to offer 20 mln shares of its common stock ), CRUS -5.7% (in symp with AAPL), FXCM -5.4% (Board approved a 1-for-10 reverse split), FCSC -2.1% (commenced a public offering of common stock; size and price not disclosed), RGLS -4.9% (still checking), NXPI -4.8% (following AAPL results), BIIB -4.4% (disappointing Phase 1b data for 6 mg dose of aducanumab), AVGO -4.1% (following AAPL results), BHP -3.7% (reports FY15 gold production), STM -3.1% (in symp with AAPL), INVN -2.9% (following AAPL results), FIT -2.7% (cont vol post IPO), TSLA -1.8% (trading lower with the mkt), LLY -1.8% (announces results regarding solanezumab, that indicated the preservation of treatment effect in patients with mild Alzheimer's disease who received the drug early), FCSC -1.7% (commences a public offering of common stock), FB -1.6% (trading lower with the mkt),TWTR -1.2% (trading lower with the mkt), MU -1.1% (in symp with AAPL), DVAX -1% ( announces a public offering of common stock)
Analyst comments: BTU -5.8% (downgraded to Neutral from Overweight at JP Morgan), SD -3.8% (assumed with an Underperform at Credit Suisse), STM -3.1% (downgraded to Neutral at Citigroup), ALV -1.9% (downgraded to Neutral from Buy at BofA/Merrill ), AINV -1.7% (downgraded to Equal Weight from Overweight at Barclays ), CHK -1.5% (downgraded to Neutral from Outperform at Credit Suisse), EBAY -1% (downgraded to Mkt Perform from Outperform at Raymond James)